ACTRN12605000696695终止不适用
Double-blind, Double-dummy, Randomised, Parallel-Arm Equivalence [Non-Inferiority] Study Comparing Hydromorphone Hydrochloride Extended-Release [HHER] Capsules to MS Contin Tablets, Dosed at a Ratio of 1:7.5 to relieve pain, in Cancer or Non-Cancer Patients with a History of Moderate to Severe Pain
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •1. Treatment with opioid analgesic for at least past 4 weeks. 2. Prior opioid analgesic equivalent to 80mg morphine or greater. 3. Pain score less than, or equal to, 4 over 24 hour period for last two consecutive days. 4. Rescue doses less than, or equal to, three doses over 24 hour period for the last two consecutive days.
排除标准
- •History of alcohol or drug abuse, unstable pain, high dose systemic corticosteroid therapy excluded.
研究者
相似试验
进行中（未招募）
1 期
Clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagusMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disorderseosinophilic esophagitisEUCTR2020-001314-37-PTDr. Falk Pharma GmbH242
进行中（未招募）
1 期
clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagusMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disorderseosinophilic esophagitisEUCTR2020-001314-37-ATDr. Falk Pharma GmbH242
进行中（未招募）
1 期
clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagusMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disorderseosinophilic esophagitisEUCTR2020-001314-37-DEDr. Falk Pharma GmbH242
进行中（未招募）
不适用
Randomised, double-blind, double-dummy, parallel trial comparing a novel DPI with 250 µg fluticasone versus Flutide® 250 Diskus® in patients with persistent asthma - Inhalation study fluticasone DPIPersistent Asthma in adultsMedDRA version: 9.1Level: LLTClassification code 10049106Term: Asthma chronicEUCTR2006-007073-75-DEmibe GmbH Arzneimittel
进行中（未招募）
不适用
Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel. - MASCOTEUCTR2005-003119-62-CZsanofi-aventis recherche & développement580